We provide you with 20 years of free, institutional-grade data for NUVL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of NUVL. Explore the full financial landscape of NUVL stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-07 | 1861560 | NUVL | 10-Q | Url |
| 2025-05-08 | 1861560 | NUVL | 10-Q | Url |
| 2025-02-27 | 1861560 | NUVL | 10-K | Url |
| 2024-11-12 | 1861560 | NUVL | 10-Q | Url |
| 2024-08-08 | 1861560 | NUVL | 10-Q | Url |
| 2024-05-09 | 1861560 | NUVL | 10-Q | Url |
| 2024-02-27 | 1861560 | NUVL | 10-K | Url |
| 2023-11-14 | 1861560 | NUVL | 10-Q | Url |
| 2023-08-10 | 1861560 | NUVL | 10-Q | Url |
| 2023-05-11 | 1861560 | NUVL | 10-Q | Url |
| 2023-03-16 | 1861560 | NUVL | 10-K | Url |
| 2022-11-10 | 1861560 | NUVL | 10-Q | Url |
| 2022-08-10 | 1861560 | NUVL | 10-Q | Url |
| 2022-05-12 | 1861560 | NUVL | 10-Q | Url |
| 2022-03-29 | 1861560 | NUVL | 10-K | Url |
| 2021-11-10 | 1861560 | NUVL | 10-Q | Url |
| 2021-09-08 | 1861560 | NUVL | 10-Q | Url |
| 2021-07-07 | 1861560 | NUVL | S-1 | Url |
Nuvalent, Inc.(NASDAQ:NUVL) 
Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant muta...
Website: http://www.nuvalent.com
Founded: 2017
CEO: James Porter
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about NUVL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.